How much did DocMorris’ revenue increase in the first nine months of 2025?

DocMorris increased its external revenue by 9.5 per cent to CHF 854.3 million in the first nine months of 2025. The company said this was despite the discontinuation of the Zur Rose brand in Germany at the end of 2024.

How did DocMorris’ revenue perform in the third quarter of 2025?

DocMorris’ third-quarter sales increased by 8.1 per cent to CHF 282.3 million. The company said this was despite the usual seasonal slowdown caused by the summer holidays.

Which DocMorris segment delivered the strongest revenue growth in the first nine months of 2025?

The Germany segment grew by 10.0 per cent in the first nine months of 2025, while revenue in the Europe segment increased by 2.7 per cent with a focus on profitability.

How quickly did DocMorris’ Rx revenue grow in the first nine months of 2025?

DocMorris’ external Rx revenue rose by 37.9 per cent in the first nine months of 2025. Sequentially, Rx revenue increased by 9.2 per cent from the second to the third quarter.

How did DocMorris’ non-Rx business perform in the first nine months of 2025?

DocMorris’ non-Rx external revenue increased by 4.3 per cent in the first nine months of 2025 and grew across all areas from the second to the third quarter. Retail media and the marketplace achieved high double-digit growth, while the company said all service platforms made a disproportionately large contribution to profitability.

How much did TeleClinic’s revenue grow for DocMorris in the first nine months of 2025?

TeleClinic increased its revenue by more than 140 per cent to over CHF 17 million in the first nine months of 2025. DocMorris said TeleClinic is increasingly becoming an important part of its German business.

How many active customers did DocMorris have in the first nine months of 2025?

DocMorris’ number of active customers increased from 10.3 million to 10.6 million in the first nine months of 2025. In the third quarter, the number increased from 10.5 million to 10.6 million.

What is the DocMorris health companion and when did its full rollout begin?

The AI-based DocMorris health companion became available to all users of the DocMorris app at the beginning of October 2025 through the full rollout of the beta phase of the DocMorris Assistant. DocMorris said the associated digital health ecosystem activities are being consolidated under Executive Board member David Masó as Chief AI Health Officer.

Who is Andrea Skersies and what role will she have at DocMorris?

Andrea Skersies was appointed Chief Commercial Officer and member of the Executive Board at DocMorris. She will oversee all e-commerce activities in the Germany and Europe segments, while DocMorris also reduces one management level and adjusts further management structures.

What did DocMorris say about its 2025 outlook and profitability targets?

DocMorris confirmed its revenue and earnings guidance for 2025, as well as its target of reaching EBITDA breakeven in the course of 2026 and free cash flow breakeven in the course of 2027. CFO Daniel Wüest said the company was on track to achieve its 2025 outlook and was focusing on efficiency gains and cost reductions to improve profitability.

What does DocMorris do and how does its business operate?

DocMorris AG is a Swiss-based company operating in online pharmacy, telemedicine and marketplace services, with strong brands in Germany and other European countries. Deliveries are mainly made from its highly automated logistics centre in Heerlen, the Netherlands, while TeleClinic connects patients with more than 5,000 physicians and DocMorris operates health and personal care marketplaces in Southern Europe.

Where are DocMorris AG shares listed and what is the ticker symbol?

The shares of DocMorris AG are listed on the SIX Swiss Exchange. The source gives securities number 4261528, ISIN CH0042615283 and ticker DOCM.

What are the next scheduled DocMorris investor and company events?

DocMorris lists Sales 2025 for 20 January 2026, 2025 full-year results and outlook 2026 for 19 March 2026, and a Q1/2026 trading update for 16 April 2026. Further listed events are the Annual General Meeting in Zurich on 12 May 2026, 2026 half-year results on 19 August 2026 and a Q3/2026 trading update on 15 October 2026.

Home
News Intelligence
DocMorris AG
DocMorris reports higher nine-month revenue as Rx growth accelerates

Back to all DocMorris AG press releases

DocMorris AG

SIX:DOCM

DocMorris reports higher nine-month revenue as Rx growth accelerates

Published Thursday, 16 October 2025, 05:00 AM

Get alerts

Plain English summaries when DocMorris AG announces news.

At a glance

Company: DocMorris AG
Listings: SIX:DOCM
Announcement type: Trading update
Published: Thursday, 16 October 2025, 05:00 AM
Reporting period: first nine months 2025
Source announcement: eqs-news.com

Key figures
Measure	Figure	Period
External revenue	CHF 854.3 million	first nine months 2025
Sales	CHF 282.3 million	the third quarter

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

DocMorris AG (DOCM) reported first-nine-month revenue growth and announced changes involving its AI health companion and management.

External revenue increased 9.5 per cent to CHF 854.3 million; third-quarter sales increased 8.1 per cent to CHF 282.3 million.
Nine-month external Rx revenue rose 37.9 per cent; quarterly Rx revenue increased 9.2 per cent from the second to third quarter.
In nine months, non-Rx external revenue increased 4.3 per cent; TeleClinic rose more than 140 per cent to over CHF 17 million.
The AI-based DocMorris health companion became available to all app users at the beginning of October; David Masó became CAHO.
Andrea Skersies was appointed CCO and Executive Board member, with DocMorris bundling e-commerce activities in Germany and Europe under her.

Active customers rose from 10.3 million to 10.6 million. Management confirmed 2025 revenue and earnings guidance, EBITDA breakeven in the course of 2026, and free cash flow breakeven in the course of 2027.

Investor FAQs

DocMorris reported revenue growth in the first nine months of 2025, accelerating sequential Rx growth, increases across its non-Rx business and the full rollout of its AI-based DocMorris health companion. It also announced the appointments of Andrea Skersies as Chief Commercial Officer and Executive Board member, and David Masó as Chief AI Health Officer.

Source announcement

Company: DocMorris AG
Title: DocMorris accelerates sequential Rx growth and increases non-Rx revenue
Published: Thursday, 16 October 2025, 05:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…